Europe PMC
open access
Genetically engineered hypoimmunogenic iPSCs: Strategies and considerations for clinical applications
Induced pluripotent stem cell (iPSC)-based therapies are rapidly advancing toward clinical implementation, with increasing numbers of trials and approvals for allogeneic iPSC-derived cell products. However, immune rejection remains a major barrier to the broad application of "off-the-shelf" allogene
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T Cells#1171207
- Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)#898919
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies#859115
- Younger vs. Older Donors in Allo-HSCT: TTE#995568
- Induced Pluripotent Stem Cell-Derived Small-Diameter Vascular Grafts: Scaffold Design, Immune Engineering, and Clinical Translation.#645273
Record · ID 1175095
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive